Skip to main content
. Author manuscript; available in PMC: 2012 Feb 15.
Published in final edited form as: Clin Cancer Res. 2010 Nov 24;17(4):896–906. doi: 10.1158/1078-0432.CCR-10-2463

Figure 3. Correlative studies related to relapse.

Figure 3

Figure 3

Figure 3

A, Serum C-reactive peptide level (CRP) was determined prior to initiation of treatment and was correlated to relapse. B, Th17 inducibility, before and 6 months after treatment, was quantified by flow cytometry and the difference was correlated to relapse. C, Absolute lymphocyte count (ALC) was drawn prior to and four weeks after initiation of treatment, and the difference was correlated to relapse.